- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00050752
Leiomiomatosi ereditaria Cancro a cellule renali - Studio della causa genetica e della predisposizione al cancro renale
Leiomiomatosi ereditaria Cancro a cellule renali (HLRCC): identificazione del gene della malattia e caratterizzazione della predisposizione al cancro renale
This study will investigate what causes hereditary leiomyomatosis renal (kidney) cell cancer, or HLRCC, and how the disease is related to the development of kidney tumors. Leiomyomas are benign (non-cancerous) tumors arising from smooth muscle. HLRCC can cause various health problems. Some people develop red bumps on their skin that can be painful at times. Some women with HLRCC can develop leiomyomas of the uterus. In some families, people with HLRCC develop kidney tumors. This study will try to determine:
- What gene changes (mutations) cause HLRCC
- What kind of kidney tumors develop in HLRCC and how they grow
- What the chance is that a person with HLRCC will develop a kidney tumor
People with known or suspected HLRCC (and their family members of any age) may be eligible for this study. This includes people in families in which one or more members has skin leiomyoma and kidney cancer; skin leiomyoma and uterine leiomyoma; multiple skin leiomyomas; kidney cancer and uterine leiomyomas, or kidney cancer consistent with HLRCC, including, but not limited to, collecting duct or papillary, type II. Candidates will be screened with a physical examination, family history, and, for affected family members, a review of medical records, including pathology slides and computed tomography (CT) or magnetic resonance imaging (MRI) scans.
Participants will undergo tests and procedures that may include the following:
-
Review of medical records, x-rays, and tissue slides
-
Physical examination and family history
-
Skin examination
-
Gynecological examination for women
-
Interviews with a cancer doctor, cancer nurses, kidney surgeon, and genetic counselor
-
Blood tests for:
- Genetic research to identify the gene responsible for HLRCC
- Evaluation of liver, kidney, heart, pancreas, and thyroid function
- Complete blood count and clotting profile
- Pregnancy test for pre-menopausal women
- PSA test for prostate cancer in men over age 40
-
CT or MRI scans (for participants 15 years of age and older only)
-
Skin biopsy (surgical removal of a small sample of skin tissue)
-
Cheek swab or mouth rinse to collect cells for genetic analysis
-
Medical photographs of lesions
-
Questionnaire
When the tests are completed, participants will discuss the results with a doctor and possibly a genetic nurse or genetic counselor. The genetic findings will not be revealed to participants because their meaning and implications may not yet be understood. Participants may be asked to return to NIH from every 3 months to every 3 years, depending on their condition, for follow-up examinations and tests.
Panoramica dello studio
Stato
Descrizione dettagliata
Background:
- Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is a rare autosomal dominantly inherited disorder which confers susceptibility to develop cutaneous and uterine leiomyomas and renal cell carcinoma.
- HLRCC is caused by mutations in the Krebs cycle enzyme, fumarate hydratase localized on chromosome 1q42.3-q43.
Objectives:
- Define the risk of developing renal cancer, cutaneous leiomyoma and uterine leiomyoma in this hereditary cancer syndrome
- Define the types and characteristics (including patterns of growth) of renal cancer associated with HLRCC
- Determine the incidence and characteristics of HLRCC-associated fumarate hydratase gene mutations
- Determine genotype/phenotype correlations
- Determine if other genes cause HLRCC
Eligibility:
-
Individuals that meet one or more of the following criteria:
-
Suspected or known to have phenotype or genotype suggestive of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC), such as:
- Cutaneous leiomyoma and kidney cancer
- Cutaneous leiomyoma and uterine leiomyoma
- Multiple cutaneous leiomyoma
- Kidney cancer and uterine leiomyomata
or
-Renal tumor histology consistent with HLRCC including, but not limited to: Collecting Duct and/or Papillary, Type II
or
-Are a relative (related by blood) of an individual with a confirmed or suspected diagnosis of HLRCC
Design:
- These rare biological families will be recruited to genetically confirm diagnosis, determine size and location of renal tumors, size at presentation, growth rate and metastatic potential of renal tumors.
- Genetic testing will be offered to gain appreciation of the effect of mutations on the relative activity of various germline and somatic mutations.
- We will determine if there is a relationship between mutation and disease phenotype.
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Deborah A Nielsen, R.N.
- Numero di telefono: (240) 760-6247
- Email: deborah.nielsen@nih.gov
Backup dei contatti dello studio
- Nome: W. Marston Linehan, M.D.
- Numero di telefono: (240) 858-3700
- Email: linehanm@mail.nih.gov
Luoghi di studio
-
-
Maryland
-
Bethesda, Maryland, Stati Uniti, 20892
- Reclutamento
- National Institutes of Health Clinical Center
-
Contatto:
- For more information at the NIH Clinical Center contact National Cancer Institute Referral Office
- Numero di telefono: 888-624-1937
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
An individual (including patient) from a family in which one or more family member have: cutaneous leiomyoma and kidney cancer, cutaneous leiomyoma and uterine leiomyoma, multiple cutaneous leiomyoma, kidney cancer and uterine leiomyomata, renal tumor histology consistent with HLRCC including, but not limited to: Collecting Duct and/or Papillary, Type II.
Descrizione
-
INCLUSION CRITERIA:
-
Individuals that meet one or more of the following criteria:
-
Suspected or known to have phenotype or genotype suggestive of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC), such as:
- Cutaneous leiomyoma and kidney cancer; or
- Cutaneous leiomyoma and uterine leiomyoma; or
- Multiple cutaneous leiomyoma; or
- Kidney cancer and uterine leiomyomata
-
OR
--Renal tumor histology consistent with HLRCC including, but not limited to: Collecting Duct and/or Papillary, Type II
OR
--Are a relative (related by blood) of an individual with a confirmed or suspected diagnosis of HLRCC.
- Participants must be >= 2 years of age.
- All participants and parents/guardians, for children younger than 18 years of age, must sign an informed consent document indicating their understanding of the investigational nature and the risks of this study before any protocol related studies are performed.
EXCLUSION CRITERIA:
None
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: CASE_ONLY
- Prospettive temporali: PROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
|---|
|
1 / Individuals
Individuals with known or suspected Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC) |
|
2 / Family Members
Family members (related by blood) of individuals who have or are suspected of having Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC) |
|
3 / Non-Biologic Family Members
Spouses enrolled primarily for linkage analysis (Spouses have been removed from the inclusion criteria for this study. This closed cohort is for spouses previously enrolled on study.) |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Determine the incidence and characteristics of HLRCC-associated fumarate hydratase gene mutations.
Lasso di tempo: on-going
|
Molecular genetic differences between normal and tumorigenic fumarate hydratase (fumerase) mutations. |
on-going
|
|
Determine the clinical manifestations of HLRCC
Lasso di tempo: on-going
|
Collection of blood, urine and/or benign and malignant tissue. |
on-going
|
|
Determine if other genes cause HLRCC.
Lasso di tempo: on-going
|
Molecular genetic differences between normal and tumorigenic cells. |
on-going
|
|
Determine genotype/phenotype correlations.
Lasso di tempo: on-going
|
Detection and expression analysis of gene(s). |
on-going
|
|
Define the types and characteristics (including patterns of growth) of renal cancer associated with HLRCC.
Lasso di tempo: on-going
|
Detection and expression analysis of gene(s). |
on-going
|
|
Define the risk of developing renal cancer, cutaneous leiomyoma and uterine leiomyoma in this hereditary cancer syndrome.
Lasso di tempo: on-going
|
Collection of blood, urine and/or benign and malignant tissue. |
on-going
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: W. Marston Linehan, M.D., National Cancer Institute (NCI)
Pubblicazioni e link utili
Pubblicazioni generali
- Linehan WM, Lerman MI, Zbar B. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA. 1995 Feb 15;273(7):564-70. No abstract available.
- Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993 May 28;260(5112):1317-20. doi: 10.1126/science.8493574.
- Zbar B, Tory K, Merino M, Schmidt L, Glenn G, Choyke P, Walther MM, Lerman M, Linehan WM. Hereditary papillary renal cell carcinoma. J Urol. 1994 Mar;151(3):561-6. doi: 10.1016/s0022-5347(17)35015-2.
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stimato)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie
- Malattie urogenitali maschili
- Malattie renali
- Malattie urologiche
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Neoplasie per tipo istologico
- Neoplasie urologiche
- Neoplasie, Connettivo e Tessuto Molle
- Neoplasie, tessuto muscolare
- Neoplasie renali
- Leiomioma
Altri numeri di identificazione dello studio
- 030066
- 03-C-0066
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
All IPD recorded in the medical record will be shared with intramural investigators upon request. @@@@@@In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP.
Periodo di condivisione IPD
Clinical data available during the study and indefinitely.@@@@@@Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.
Criteri di accesso alla condivisione IPD
Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.@@@@@@Genomic data are made available via dbGaP through requests to the data custodians.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- ICF
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .